Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials

Key Takeaways

• Airway Therapeutics' zelpultide alfa targets BPD prevention in infants 22‑27 weeks
• BPD affects 10,000‑15,000 U.S. newborns annually, causing long‑term complications
• Orphan trials need lean designs with early safety and efficacy readouts
• NICU enrollment demands rapid consent and dual‑team blinding, complicating trial logistics
• Site qualification emphasizes patient flow and avoiding transport risks

Pulse Analysis

Bronchopulmonary dysplasia remains one of the most common severe respiratory conditions in preterm infants, affecting roughly 10,000 to 15,000 babies in the United States each year. The disease stems from a vicious cycle of lung injury, inflammation, and infection triggered by necessary ventilatory support, leading to chronic lung dysfunction, neurodevelopmental delays, and heightened healthcare costs throughout life. As an orphan indication, BPD has seen few therapeutic breakthroughs, creating a sizable market gap for interventions that can interrupt this cycle early in the neonatal period.

Conducting trials in the NICU environment presents unique obstacles that differ sharply from adult drug development. Patient enrollment must occur within hours of birth, requiring swift parental consent and coordination across multiple clinical teams. Blinded study designs are further complicated when investigational agents are delivered endotracheally, often unblinding the administering clinician and necessitating a separate, blinded assessment team. Because the eligible population is inherently small, sponsors like Airway Therapeutics are forced to adopt lean trial architectures that prioritize early safety and efficacy readouts, minimizing sample size while still satisfying regulatory rigor.

Airway Therapeutics’ focus on zelpultide alfa reflects a strategic bet on preventive therapy rather than rescue treatment, aligning with regulators’ demand for clear, homogeneous patient cohorts and robust endpoints. If the Phase IIb dose‑selection and subsequent Phase III studies demonstrate meaningful reductions in BPD incidence, the company could capture a multi‑billion‑dollar market while setting a precedent for future neonatal orphan drug programs. Success would also alleviate long‑term clinical and economic burdens for families and health systems, reinforcing the importance of innovative trial designs in high‑risk pediatric populations.